Abstract Competition Winners

First Place 

Abstract #1 – University of Chicago School of Medicine (Multi-Institutional Clinical Trial) and Candel Therapeutics

Title: Safety and Feasibility of Intraprostatic Injection of CAN-2409 or Placebo followed by Valacyclovir in Patients on Active Surveillance for Prostate Cancer (ULYSSES Trial)

Submitted by: Scott Eggener, MD, University of Chicago School of Medicine

Second Place (Tied)

Abstract #7 – Washington University School of Medicine in St. Louis, Leeds Teaching Hospitals NHS Trust  and Blue Earth Diagnostics

Title: Impact of 18F-Fluciclovine PET/CT on Plans for ADT in Patients with Biochemical Recurrence of Prostate Cancer; Analysis from Two Prospective Clinical Trials

Submitted by: Gerald Andriole, MD, Washington University School of Medicine

Abstract #14 – Cleveland Diagnostics

Title: IsoPSA®: Clinical Performance of a Single Parameter, Structure Based Test for High Grade Prostate Cancer in a Large, Multicenter, Prospective Validation Trial

Submitted by: Mark Stovsky, MD, Chief Medical Officer

Third Place

Abstract #16 – Lantheus Medical Imaging

Title: OSPREY and CONDOR: Results from Two Registrational Clinical Studies Assessing the Diagnostic Performance of Piflufolastat F 18 (PYLARIFY®) PET/CT in Patients with High-Risk and Recurrent Prostate Cancer

Submitted by: Bela Denes, MD

 

Published Abstracts (In Order of Submission)

Abstract #1 – University of Chicago School of Medicine (Multi-Institutional Clinical Trial) and Candel Therapeutics

Safety and Feasibility of Intraprostatic Injection of CAN-2409 or Placebo followed by Valacyclovir in Patients on Active Surveillance for Prostate Cancer (ULYSSES Trial)

Abstract #2 – Dartmouth University

Ex Vivo Prostate Study of an Enhanced 12-Core Biopsy with Electrical Impedance

Abstract #3 – Stanford University

A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy

Abstract #4 – Stanford University

A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer

Abstract #5 – Northwestern University

Assessing the Negative Predictive Value and Accuracy of Multiparametric MRI to Predict Clinically Significant Prostate Cancer in Biopsy Naïve Men Across Racial Groups

Abstract #6 – University of Miami and Exosome Diagnostics/Bio-Techne

Development of Exosome-based Plasma RNA Biomarkers for High-Risk Prostate Cancer

Abstract #7 – Washington University School of Medicine in St. Louis, Leeds Teaching Hospitals NHS Trust and Blue Earth Diagnostics

(Publication Pending Submission of the Release Form)

Abstract #8 – University of Miami

Establishing the Best Threshold for Biopsy in mpMRI Negative or Indeterminate Men using Data from a Large Multi-Institutional Cohort of Men undergoing mpMRI, 4Kscore and Prostate Biopsy

Abstract #9 – Yale School of Medicine

MRI Monitoring for Focal Ablation Series

Abstract #10 – Yale School of Medicine

Discriminative Ability of Decipher to Predict Biopsy Upgrade on Active Surveillance

Abstract #11 – Yale School of Medicine

Association Between Age at the Time of Surgery and Recovery of Urinary Continence in Men Undergoing Radical Prostatectomy

Abstract #12 – Yale School of Medicine

Association of High-Grade Prostatic Intraepithelial Neoplasia, Atypical Small Acinar Proliferation, or Perineural Invasion with the Risk of Upgrading in Active Surveillance Cohort In the MRI-Ultrasound Fusion Biopsy Era

Abstract #13 – Northwestern University

Association of Genetic Ancestry and Sociodemographic Factors with the Genomic Prostate Score (GPS)

Abstract #14 – Cleveland Diagnostics (Multi-Institutional Clinical Trial)

(Publication Pending Submission of the Release Form)

Abstract #15 – Cleveland Diagnostics (Multi-Institutional Clinical Trial)

(Publication Pending Submission of the Release Form)

Abstract #16 – Lantheus Medical Imaging (Multi-Institutional Clinical Trial)

OSPREY and CONDOR: Results from Two Registrational Clinical Studies Assessing the Diagnostic Performance of Piflufolastat F 18 (PYLARIFY®) PET/CT in Patients with High-Risk and Recurrent Prostate Cancer

Abstract #17 – University of Miami Miller School of Medicine

The Performance of mpMRI and the 4Kscore for Predicting Progression on Active Surveillance; Results from a Single Institution Prospective Study

Abstract #18 – University of Miami

A Multi-Institutional Study of 1111 Men With 4Kscore, Multiparametric MRI and Prostate Biopsy

Abstract #19 – Memorial Sloan Kettering Cancer Center and Telix Pharmaceuticals

Safety of [68Ga]Ga-PSMA-11 prepared with the cold kit used in the Pivotal Lu-PSMA 617 Vision trial for selection of PSMA positive patients
Call for Abstracts
5th Global Summit